4 February 2022
Change in Substantial Holder
3 February 2022
VIRALEZE™ sales and distribution in Saudi Arabia and GCC
1 February 2022
Appendix 3H
1 February 2022
Appendix 2A
1 February 2022
Appendix 2A
28 January 2022
Quarterly Cashflow and Activities Report
20 January 2022
Starpharma receives $7.7M R&D tax incentive refund
23 December 2021
Appendix 3H
16 December 2021
Shareholder Newsletter
14 December 2021
VIRALEZE™ antiviral nasal spray registered in Saudi Arabia
13 December 2021
VIRALEZE™ successfully launched in Vietnam
8 December 2021
US Biopharma DEP Research Agreement – Additional Information
7 December 2021
Starpharma signs DEP Research Agreement with US Biopharma Co
3 December 2021
Appendix 3G
3 December 2021
Change in Director's Interest Notice - J Fairley
3 December 2021
VIRALEZE™ distribution agreement and launch in Vietnam
1 December 2021
VIRALEZE™ registered in Vietnam with launch this week
30 November 2021
AGM Results
30 November 2021
AGM Chairman address and CEO presentation
25 November 2021
Positive DEP® phase 2 interim results in prostate cancer

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com


This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.